You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
遠大醫藥(00512.HK):2023年收益同比增長10.1%至105.3億港元 擬派末期息每股26港仙
格隆匯 03-20 06:20

格隆匯3月20日丨遠大醫藥(00512.HK)發佈公吿,截至2023年12月31日止年度,集團的業務穩健增長,收益約港幣105.3億元,同比增長約10.1%。如撇除人民幣與港元匯率變動的影響,即較2022年同期相比上升約15.8%。於本回顧期間,公司擁有人應占期內溢利約為港幣18.8億元,同比下降約9.6%。本期的公司擁有人應占期內正常化溢利約為20.36億元,較去年同期下降約4.7%。如撇除人民幣與港元匯率變動的影響,即較2022年同期相比上升約0.2%。期內集團的毛利率錄得約62.0%,而2022年同期即約為62.2%。

集團基於良好的業績表現,以為推動全體股東共用公司經營發展成果,切實保護股東利益為目標,今年董事會建議派發2023年年度末期股息每股26港仙,共約港幣9.05億元。截至2023年12月31日止,集團繼續投入資源用於在研項目的推進及創新項目的引進,研發費用加上資本化研發支出、新項目的預付款及其他投入,集團於研發工作及項目的投入約港幣14.41億元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account